|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Then we discovered that silencing EMP1 inhibited glioma cell invasion and proliferation through inhibiting the PI3K-AKT signaling pathway.
|
31111534 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
|
31758290 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway.
|
31787462 |
2020 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LINC00673 silencing inhibits cell migration and invasion by suppressing PI3K/AKT signaling in glioma.
|
29621055 |
2018 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, knockdown of TRIM37 significantly reduced the levels of phosphorylated PI3K and Akt in U87MG cells, and an activator of PI3K/Akt signaling (SC79) partly reversed the inhibitory effects of si-TRIM37 on glioma cell proliferation and migration.
|
29324313 |
2018 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, we reported that tyrosine-protein phosphatase non-receptor type 11 (SHP-2) and phosphatidylinositol 3-kinase (PI3K) mediate platelet-derived growth factor receptor-α (PDGFRα)-promoted glioma tumor growth and invasion.
|
21996738 |
2012 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reasons for treatment failure include poor penetration of agents into the brain and observations that blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma.
|
28696243 |
2018 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 is commonly used to inhibit glioma cell growth via regulation of the PI3K/AKT signaling pathway.
|
28401302 |
2017 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of miR-770 indicates a favorable prognosis and suppresses tumorigenesis by modulating PI3K-AKT pathway in glioma.
|
31002138 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR signaling is a valuable treatment target for human glioma.
|
29228741 |
2017 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.
|
29774498 |
2018 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results illustrate the novel role of T11TS immunotherapy in ameliorating the PI3K pathway in T-cells in glioma-bearing animals to enhance T-cell survival, according greater defense against glioma.
|
28608562 |
2018 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we uncovered that BCAR4 activated PI3K/AKT signaling pathway in glioma through upregulating EGFR and interacting with it.
|
31173355 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blocking the phosphoinoside 3-kinase (PI3K)/Akt pathway with LY294002 or si-Akt also suppressed the self-renewal of sphere-cultured glioma cells.
|
22249269 |
2012 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
|
19705067 |
2010 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI-3-K stimulation seems to be critical for CD95 receptor signalling since, first, inhibition of PI-3-K prevents CD95-mediated apoptosis and, second, CD95 receptor ligation fails to induce tyrosine phosphorylation or activation of PI-3-K in CD95-resistant glioma cells.
|
9446703 |
1998 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway.
|
17159987 |
2007 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study was conducted with aims of exploring the ability of MCL1 silencing to influence glioma cell senescence and apoptosis through the mediation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.
|
30296359 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis.
|
16170333 |
2005 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, proteins regulated by phosphoinositide 3-kinase (PI3K)/Akt signaling, are among the top downregulated genes in gliomas associated with high percentage of IDH1 and IDH2 mutations.
|
24771584 |
2014 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We did whole exome sequencing for 11 GBM-PN cases and found that the percentage of TP53, PIK3CA, PIK3R1, or PTEN mutation in our GBM-PN cases (72.7%, 27.3%, 27.3%, and 27.3% respectively) was much higher than that in cases in TCGA GBM 2008, TCGA GBM 2013, and TCGA lower-grade glioma databases.
|
30715630 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The detailed study of these candidate genes and the molecular pathways regulating PI3K activation reveal that they are promising targets for the clinical management of patients with glioma.
|
18260157 |
2008 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We tested the biologic effects of a selective PI3K inhibitor NVP-BKM120 in a set of glioma cell lines.
|
22065080 |
2012 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrated a novel cellular mechanism that was dependent of the lncRNA-XIST/miR-126/IRS1/PI3K/Akt pathway in enhanced glucose metabolism in glioma.
|
31680298 |
2020 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
|
28423515 |
2017 |